Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 75.0%

Neg 75% Neu 0% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.